Evidence map›Paper›PMID 25986661›Full record

ArticleDiabetes care2015

Early Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe).

William H Herman, Wen Ye, Simon J Griffin, Rebecca K Simmons, Melanie J Davies, Kamlesh Khunti, Guy E H M Rutten, Annelli Sandbaek, Torsten Lauritzen, Knut Borch-Johnsen and 2 more

2 registry-linked trialsOpen access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 142 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 3 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05609266 completednot on this map

Validation of Non-invasive Risk Models for Prediction of Incident Type 2 Diabetes in a Swedish Population

TypeobservationalSponsorUmeå UniversityRan1990 to 2020Enrolled115,642ConditionsType2diabetes
NCT07742917 narecruitingnot on this mapstarted 2026, after this paper: background citation

Application of a Precision Lifestyle Medicine Clinical Program for a Sample of IFHAS Screening Cohort

TypeinterventionalSponsorInstitute for Healthier Living Abu DhabiRan2026 to 2027Enrolled150ConditionsObese Adults, BMI/Body Composition, Cardiometabolic Risk, Cardiovascular Disease RiskArmsPrecision Lifestyle Medicine Program, Standard IFHAS Care
3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 3 syntheses or guidelines pooled it, 330 citations in OpenAlex.

  1. Pooled it
  2. Screening for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020
    Pooled it
  3. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.The Journal of clinical endocrinology and metabolism · 2019
    Guideline
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Therapeutic Inertia in an Insured Population with Type 2 Diabetes in the United States: A Retrospective Cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

William H HermanDepartments of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, MI wherman@umich.edu.
Wen YeSchool of Public Health, University of Michigan, Ann Arbor, MI.
Simon J GriffinMedical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, U.K.
Rebecca K SimmonsMedical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, U.K.
Melanie J DaviesLeicester Diabetes Centre, University of Leicester, Leicester General Hospital, Leicester, U.K.
Kamlesh KhuntiLeicester Diabetes Centre, University of Leicester, Leicester General Hospital, Leicester, U.K.
Guy E H M RuttenDepartment of Primary Care, Julius Center, University Medical Center, Utrecht, the Netherlands.
Annelli SandbaekInstitute of Public Health, Section of General Practice, Aarhus University, Aarhus, Denmark.
Torsten LauritzenInstitute of Public Health, Section of General Practice, Aarhus University, Aarhus, Denmark.
Knut Borch-JohnsenHolbaek Hospital, Holbæk Sygehus, Holbaek, Denmark.
Morton B BrownSchool of Public Health, University of Michigan, Ann Arbor, MI.
Nicholas J WarehamMedical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, U.K.
University of Michigan–Ann Arbor · USAarhus University · DKHolbæk Sygehus · DKUniversity Medical Center Utrecht · NL

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
Department of Health 08/116/300Department of Health RP-PG-0606-1259Medical Research Council G0001164Medical Research Council MC_U106179471Medical Research Council MC_U106179474Medical Research Council MC_UU_12015/1Medical Research Council MC_UU_12015/4NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK092926NIDDK NIH HHS P30DK092926Wellcome Trust
6 · The paper itself

Abstract

objectiveTo estimate the benefits of screening and early treatment of type 2 diabetes compared with no screening and late treatment using a simulation model with data from the ADDITION-Europe study. RESEARCH DESIGN AND

methodsWe used the Michigan Model, a validated computer simulation model, and data from the ADDITION-Europe study to estimate the absolute risk of cardiovascular outcomes and the relative risk reduction associated with screening and intensive treatment, screening and routine treatment, and no screening with a 3- or 6-year delay in the diagnosis and routine treatment of diabetes and cardiovascular risk factors.

resultsWhen the computer simulation model was programmed with the baseline demographic and clinical characteristics of the ADDITION-Europe population, it accurately predicted the empiric results of the trial. The simulated absolute risk reduction and relative risk reduction were substantially greater at 5 years with screening, early diagnosis, and routine treatment compared with scenarios in which there was a 3-year (3.3% absolute risk reduction [ARR], 29% relative risk reduction [RRR]) or a 6-year (4.9% ARR, 38% RRR) delay in diagnosis and routine treatment of diabetes and cardiovascular risk factors.

conclusionsMajor benefits are likely to accrue from the early diagnosis and treatment of glycemia and cardiovascular risk factors in type 2 diabetes. The intensity of glucose, blood pressure, and cholesterol treatment after diagnosis is less important than the time of its initiation. Screening for type 2 diabetes to reduce the lead time between diabetes onset and clinical diagnosis and to allow for prompt multifactorial treatment is warranted.

Indexed as

AdultAgedBlood GlucoseBlood PressureCholesterolComputer SimulationCritical CareDenmarkDiabetes Mellitus, Type 2Diabetic AngiopathiesEarly DiagnosisFemaleHumansMass ScreeningMiddle AgedNetherlandsBlood GlucoseCholesterol

Identifiers

PMID25986661
PMCPMC4512138
OpenAlexW2113031450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.